AIMA 2026 projects ✦ Project VIII ✦ Neurology

Alzheimer’s disease before memory fails: early diagnosis & progression

Translational

Alzheimer’s disease starts in the brain years before the first symptoms. Blood tests can now detect it, and the first disease-modifying drugs are given at the earliest symptomatic stage. Two questions have become urgent: who is on this path, and how fast will each person progress? We will build models that answer both, with honest uncertainty, across cohorts.

In partnership with

  • Carnegie Mellon University
  • Stony Brook University

The cascade, and one person’s future

Schematic after the hypothetical model of dynamic biomarkers1. Curves, timings and people are illustrative, not patient data.

Why now

  • A p-tau217 blood test reached about 90% accuracy, against 61% for primary-care physicians and 73% for specialists2. The FDA cleared the first blood test to aid diagnosis in May 20253.
  • Lecanemab and donanemab slowed decline in early symptomatic disease4,5, so finding people early now changes what can be offered.
  • Multimodal AI on 51,269 people from nine cohorts reached AUROC 0.94, and neurologists did better with it6.

The gap we target

Forecasting is far from solved. In the TADPOLE challenge, 92 algorithms from 33 teams forecast diagnosis well, but none forecast a cognitive score (ADAS-Cog13) significantly better than random guessing7. Most models are trained on one cohort; real clinics lack PET or CSF; and people progress along different subtypes8.

Aim 1 · Months 1–2

Harmonize and screen

Harmonize ADNI, OASIS-3 and NACC. Baseline: predict amyloid status from MRI and routine data, as a cheap step before blood or PET tests.

Aim 2 · Months 3–4

Forecast each person

Sequence models for irregular visits and missing modalities that forecast cognition and time to MCI, with calibrated uncertainty.

Aim 3 · Months 5–6

Across cohorts

Train on one cohort, test on others; check whether progression subtypes replicate and whether they improve forecasts.

Data

  • ADNI: MRI, PET, CSF, blood, genetics (data use agreement)
  • OASIS-3: 1,378 participants, MRI and PET
  • NACC: over 56,000 participants from Alzheimer’s centers

You will learn

  • Longitudinal and time-to-event modelling
  • Neuroimaging pipelines
  • Multimodal fusion with missing data
  • Calibration and cross-cohort validation

Good fit if you

  • Like statistics and time series
  • Want your model to survive a new cohort
  • Care about neurology and ageing
1
Data

Access, harmonisation, visit alignment.

2
Imaging

MRI features and amyloid prediction.

3
Forecasting

Sequence models and uncertainty.

4
Evaluation

Cross-cohort tests and clinical framing.

✦

The plan · 6 months

From first paper to submission.

Six months, from first paper to submission, with weekly group meetings and a monthly review with mentors.

Month 1
Month 2
Month 3
Month 4
Month 5
Month 6
VIII · Alzheimer’s
Data accessHarmonize, baselinesForecasting modelsCross-cohort testsWrite & submit
Onboarding Baselines Method Experiments & studies Writing
M1
Onboard

Read 10–15 key papers, set up data access and compute, write a one-page proposal.

M2
Reproduce

Match a published baseline. Share a reproducibility report.

M3
Propose

First version of the method, defended in a mentor review.

M4
Iterate

Ablations, failure analysis, fix what the review found.

M5
Validate

External data or pilot study; freeze results.

M6
Submit

Paper, code release and a talk for the AIMA community.

Project VIII · Neurology

Want to work on
this question?

Apply through the form by November 7, 2026, choosing Project VIII, with an academic CV and a statement of purpose of up to 300 words. Interviews run November 9 to 13, and groups start around November 18. Mentors from Carnegie Mellon University · Stony Brook University.

Apply by November 7 All nine projects

References

  1. Jack et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurology 2013. DOI
  2. Palmqvist et al. Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care. JAMA 2024. DOI
  3. US Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer’s disease. Press release, 16 May 2025. link
  4. van Dyck et al. Lecanemab in Early Alzheimer’s Disease. NEJM 2023. DOI
  5. Sims et al. Donanemab in Early Symptomatic Alzheimer Disease. JAMA 2023. DOI
  6. Xue et al. AI-based differential diagnosis of dementia etiologies on multimodal data. Nature Medicine 2024. DOI
  7. Marinescu et al. The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge: Results after 1 Year Follow-up. MELBA 2021. DOI
  8. Young et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications 2018. DOI